OPCH (Option Care Health, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by OPCH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-08 | Prateek Bhatia | EVP Sp Sales & Solutions | A | — | — |
| 2026-05-22 | ERIC BRANDT | Director | A | — | — |
| 2026-05-22 | Norman L. Wright | Director | A | — | — |
| 2026-05-22 | Barbara W. Bodem | Director | A | — | — |
| 2026-05-22 | TIMOTHY P SULLIVAN | Director | A | — | — |
| 2026-05-22 | R Carter Pate | Director | A | — | — |
| 2026-05-22 | HARRY M JANSEN KRAEMER JR | Director | A | — | — |
| 2026-05-22 | Natasha Deckmann | Director | A | — | — |
| 2026-05-22 | Elizabeth D Bierbower | Director | A | — | — |
| 2026-05-21 | Collin Smyser | GC & Corporate Secretary | MIXED | — | — |
| 2026-05-07 | TIMOTHY P SULLIVAN | Director | Buy | — | — |
| 2026-05-05 | HARRY M JANSEN KRAEMER JR | Director | Buy | — | — |
| 2026-05-04 | JOHN CHARLES RADEMACHER | Chief Executive Officer | Buy | — | — |
| 2026-05-04 | Meenal Sethna | Chief Financial Officer | Buy | — | — |
| 2026-04-24 | Femi Adewunmi | Chief Medical Officer | F | — | — |
| 2026-03-03 | Michael Bavaro | Chief Human Resources Officer | Sell | — | — |
| 2026-03-03 | R Carter Pate | Director | Sell | — | — |
| 2026-02-26 | Nicole Maggio | Chief Accounting Officer | F | — | — |
| 2026-02-26 | Michael Bavaro | Chief Human Resources Officer | F | — | — |
| 2026-02-26 | JOHN CHARLES RADEMACHER | Chief Executive Officer | F | — | — |
| 2026-02-26 | Femi Adewunmi | Chief Medical Officer | F | — | — |
| 2026-02-26 | Collin Smyser | GC & Corporate Secretary | F | — | — |
| 2026-02-26 | Christopher L. Grashoff | Chief Growth Officer | F | — | — |
| 2026-02-26 | Luke Whitworth | Chief Operating Officer | F | — | — |
| 2026-02-24 | Collin Smyser | GC & Corporate Secretary | F | — | — |
| 2026-02-24 | JOHN CHARLES RADEMACHER | Chief Executive Officer | MIXED | — | — |
| 2026-02-24 | Luke Whitworth | Chief Operating Officer | F | — | — |
| 2026-02-24 | Nicole Maggio | Chief Accounting Officer | F | — | — |
| 2026-02-24 | Christopher L. Grashoff | Chief Growth Officer | F | — | — |
| 2026-02-24 | Michael Bavaro | Chief Human Resources Officer | F | — | — |
| 2026-02-19 | Collin Smyser | GC & Corporate Secretary | A | — | — |
| 2026-02-19 | Meenal Sethna | Chief Financial Officer | A | — | — |
| 2026-02-19 | Femi Adewunmi | Chief Medical Officer | A | — | — |
| 2026-02-19 | JOHN CHARLES RADEMACHER | Chief Executive Officer | A | — | — |
| 2026-02-19 | Nicole Maggio | Chief Accounting Officer | MIXED | — | — |
| 2026-02-19 | Michael Bavaro | Chief Human Resources Officer | MIXED | — | — |
| 2026-02-19 | Christopher L. Grashoff | Chief Growth Officer | MIXED | — | — |
| 2026-02-19 | Luke Whitworth | Chief Operating Officer | MIXED | — | — |
| 2025-11-04 | HARRY M JANSEN KRAEMER JR | Director | Buy | — | — |
| 2025-10-03 | Meenal Sethna | Chief Financial Officer | A | — | — |
| 2025-09-10 | Norman L. Wright | Director | Buy | — | — |
| 2025-08-21 | DAVID W GOLDING | Director | Buy | — | — |
| 2025-08-21 | TIMOTHY P SULLIVAN | Director | Buy | — | — |
| 2025-08-21 | HARRY M JANSEN KRAEMER JR | Director | Buy | — | — |
| 2025-08-21 | R Carter Pate | Director | Buy | — | — |
| 2025-08-08 | Nicole Maggio | Chief Accounting Officer | A | — | — |
| 2025-05-21 | Collin Smyser | GC & Corporate Secretary | MIXED | — | — |
| 2025-05-19 | ERIC BRANDT | Director | A | — | — |
| 2025-05-19 | Norman L. Wright | Director | A | — | — |
| 2025-05-19 | Barbara W. Bodem | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 67,860,171 | — |
| — | Director | 47,160,171 | — |
| — | Director | 37,960,171 | — |
| — | Director | 37,341,872 | — |
| — | 10%+ Owner | 10,771,926 | — |
| — | Chief Executive Officer | 695,152 | — |
| — | Director | 458,997 | — |
| — | Chief Financial Officer | 311,933 | — |
| — | Chief Operating Officer | 169,589 | — |
| — | Director | 116,525 | — |
| — | Chief Commercial Officer | 111,734 | — |
| — | Chief Financial Officer | 98,337 | — |
| — | Director | 87,216 | — |
| — | CHIEF OPERATING OFFICER | 86,760 | — |
| — | GC & Corporate Secretary | 77,512 | — |
| — | Director | 71,009 | — |
| — | Director | 61,657 | — |
| — | Director | 56,995 | — |
| — | Director | 56,994 | — |
| — | Chief Growth Officer | 44,092 | — |
| — | Chief Human Resources Officer | 33,249 | — |
| — | Director | 32,871 | — |
| — | Director | 32,002 | — |
| — | Director | 29,216 | — |
| — | Chief Accounting Officer | 28,489 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the OPCH quote page; the site-wide leaderboard is on the insider transactions hub.